Viatris Innovation GmbH
Viatris is a global healthcare company dedicated to empowering people worldwide to live healthier at every stage of life. They focus on providing access to high-quality medicines, including brands, generics, biosimilars, and over-the-counter products, across more than 165 countries. Their mission emphasizes better access leading to better health, and they aim to be a stable source of healthcare solutions through innovative and sustainable operations, leveraging their global infrastructure and expertise.
Industries
Nr. of Employees
Very Large (1000+)
Viatris Innovation GmbH
Pittsburgh, Pennsylvania, United States, North America
Products
Portfolio of branded, generic, biosimilar and over-the-counter medicines
A diverse global portfolio that includes branded medicines, generics, biosimilars and over-the-counter products across multiple therapeutic areas.
Large global product portfolio and development pipeline
Management of an extensive marketed portfolio (more than 7,500 products) and an active development pipeline (approximately 1,200 products).
Portfolio of branded, generic, biosimilar and over-the-counter medicines
A diverse global portfolio that includes branded medicines, generics, biosimilars and over-the-counter products across multiple therapeutic areas.
Large global product portfolio and development pipeline
Management of an extensive marketed portfolio (more than 7,500 products) and an active development pipeline (approximately 1,200 products).
Services
Partnership service providing market access and an integrated global infrastructure to support commercialization, regulatory and distribution of partner products.
Provision of GMP manufacturing and supply services for a range of dosage forms, including injectables, oral solids and APIs.
Integrated services supporting regulatory submissions, product registrations, commercialization strategy and post-launch activities.
Partnership service providing market access and an integrated global infrastructure to support commercialization, regulatory and distribution of partner products.
Provision of GMP manufacturing and supply services for a range of dosage forms, including injectables, oral solids and APIs.
Integrated services supporting regulatory submissions, product registrations, commercialization strategy and post-launch activities.
Expertise Areas
- GMP pharmaceutical manufacturing
- Supply chain management and distribution
- Commercialization and market access
- Clinical trial management (late-stage)
Key Technologies
- Injectable manufacturing
- Oral solid dose manufacturing
- Active pharmaceutical ingredient (API) production
- Biosimilar development
News & Updates
Viatris announced positive top-line results from their Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients with visual disturbances under mesopic, low-contrast conditions.
Viatris published their 2024 Sustainability Report focusing on building sustainable access at scale.
Viatris announced positive results from their Phase 3 study of the investigational XULANE LO™ low dose patch for birth control in women of childbearing potential.
Viatris announced positive top-line results from two pivotal Phase 3 studies of their novel fast-acting Meloxicam (MR-107A-02) for treating moderate-to-severe acute pain.
Viatris announced positive top-line results from their Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients with visual disturbances under mesopic, low-contrast conditions.
Viatris published their 2024 Sustainability Report focusing on building sustainable access at scale.
Viatris announced positive results from their Phase 3 study of the investigational XULANE LO™ low dose patch for birth control in women of childbearing potential.
Viatris announced positive top-line results from two pivotal Phase 3 studies of their novel fast-acting Meloxicam (MR-107A-02) for treating moderate-to-severe acute pain.